Industry Experts

Nisit Khandelwal is the co-founder and CEO of Cycuria Therapeutics, developing first-in-class protein-based targeted therapies for hematological cancers and beyond. He previously founded iOmx Therapeutics, a clinical-stage immuno-oncology company, where he served as CTO and Managing Director. Nisit earned his postgraduate degree at the University of Edinburgh and completed his PhD in Translational Immunology at the German Cancer Research Center (DKFZ). He is the lead inventor on multiple patents and has published extensively in cancer immunotherapy, bringing deep expertise in early-stage oncology drug discovery, translational research and innovative therapeutic platforms.